Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11745-11750. doi: 10.1073/pnas.1708420114. Epub 2017 Oct 16.

Abstract

Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencapsulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions.

Keywords: beta-cell replacement; diabetes; immune barrier; porcine islets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / surgery*
  • Diabetes Mellitus, Type 1 / surgery*
  • Diabetes Mellitus, Type 1 / therapy*
  • Female
  • Immunosuppression / methods
  • Islets of Langerhans / surgery*
  • Islets of Langerhans Transplantation / methods
  • Primates
  • Swine
  • Transplantation, Heterologous / methods